CD1D and neoplasm: Human CAR iNKT cells have demonstrated potent antitumor activity in vivo, eradicating tumor cells in a preclinical neuroblastoma model in immunodeficient mice, while retaining their physiological iTCR specificity for human CD1d-presented lipids in vitro (90).